Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Artrya Limited ( (AU:AYA) ) is now available.
Artrya Limited has entered into a three-year commercial contract with Sonic Healthcare Australia – Radiology for the utilization of its Salix® Coronary Anatomy platform. This agreement is expected to generate revenue from a Software-as-a-Service subscription model starting in the fourth quarter of the fiscal year 2025. The Salix platform, which aids in the detection of coronary artery disease, will be integrated across Sonic’s radiology centers that perform CCTA scans. This partnership marks a significant milestone for Artrya, enhancing its industry position by aligning with Australia’s second-largest diagnostic imaging provider and expanding the use of its AI-driven technology to improve heart disease diagnosis.
More about Artrya Limited
Artrya Limited is a medical technology company based in Perth, Australia, founded in 2018 and listed on the Australian Securities Exchange in 2021. The company focuses on applying artificial intelligence to improve the diagnosis of coronary heart disease. Artrya collaborates with clinicians to develop a comprehensive understanding of at-risk patients and has created deep-learning algorithms aimed at predicting and preventing acute coronary events.
YTD Price Performance: 55.66%
Average Trading Volume: 152,696
Technical Sentiment Consensus Rating: Sell
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.
